Q&A with Alina Ringaci: Improving Antibody-Drug Conjugates for Cancer Treatment
Автор: PhRMAFoundation
Загружено: 2025-10-21
Просмотров: 28
Alina Ringaci, a PhD student at Boston University, received a 2025 PhRMA Foundation Predoctoral Fellowship in Drug Delivery for her research that aims to improve antibody-drug conjugates (ADCs), a type of cancer treatment that uses special proteins called antibodies to deliver drugs directly to cancer cells. Unfortunately, ADCs often release the drug too early, before reaching the cancer cells, which then affects healthy cells and causes side effects.
Ringaci is developing a new way to connect the drug to the antibody that is more secure and stable, reducing the risk of the drug falling off before reaching a cancer cell. Watch this video to learn more about Ringaci and her research.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
![[Webinar] Manufacturing concepts for antibody-drug conjugates | Webinar](https://ricktube.ru/thumbnail/2FwI79aZTCc/mqdefault.jpg)
